Category - Developments

Developments

ENDRA, King ’s College Hospital in TAEUS clinical study for NAFLD

ENDRA Life Sciences (NASDAQ:NDRA) is partnering with King’s College Hospital, London (KCH) for a clinical study of ENDRA’s Thermo-Acoustic Enhanced Ultrasound (TAEUS) device for assessing non-alcoholic fatty liver...

December 13, 2021

Developments

Palisade Bio to receive U.S. patent to treat adhesions and postoperative ileus

The United States Patent and Trademark Office (USPTO) has granted a new U.S. patent for Palisade Bio’s (NASDAQ:PALI) lead investigational drug product, LB1148, for use in treating adhesions and postoperative ileus...

December 8, 2021

Developments

Cognetivity, Ketamine One collaborating on depression, PTSD studies

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) entered a collaborative partnership with Ketamine One Capital to study and develop assessments for depression and post-traumatic stress disorder (PTSD). In the...

December 7, 2021

Developments

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Sigyn Therapeutics (OTC: SIGY) reported that preclinical in vitro studies have validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma. Sigyn...

December 1, 2021

Developments

Altamira randomizes first patient in Bentrio trial in seasonal allergic rhinitis

Altamira Therapeutics (NASDAQ:CYTO) randomized the first patient in its NASAR trial for the clinical evaluation of Bentrio (AM-301) in seasonal allergic rhinitis (SAR). Bentrio, a drug-free nasal spray intended for...

December 1, 2021

Developments

Clene presents updated data from RESCUE-ALS Phase 2 study

Clene (NASDAQ:CLNN) presented new data from the RESCUE-ALS Phase 2 study of CNM-Au8, a catalytically active gold nanocrystal suspension, in the treatment of amyotrophic lateral sclerosis (ALS) at the 4th annual ALS ONE...

December 1, 2021

Developments

BeyondSpring receives CRL for plinabulin NDA to prevent CIN

BeyondSpring Pharmaceuticals (NASDAQ:BYSI) received a complete response letter (CRL) from the FDA for its NDA seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the...

December 1, 2021

Developments

Palisade Bio to receive European patent for LB1148

Palisade Bio (NASDAQ:PALI) was advised by the European Patent Office that it will receive a patent for its lead investigational drug product, LB1148. The patent will publish on Dec. 22, 2021, and provide protection...

November 30, 2021

Developments

Hepion receives FDA fast track designation for CRV431 to treat NASH

The FDA granted Hepion Pharmaceuticals (NASDAQ:HEPA) fast track designation for its lead drug candidate, CRV431, for the treatment of non-alcoholic steatohepatitis (NASH). CRV431 has been investigated in healthy...

November 30, 2021

Developments

Tetra Bio-Pharma posts positive initial data from ongoing Phase 2 trials of QIXLEEF

Tetra Bio-Pharma (TSX:TBP; OTCQB:TBPMF; FRA:JAM1) reported positive initial clinical data from its ongoing Phase 2 REBORN 1 and PLENITUDE trials of QIXLEEF for cancer pain. QIXLEEF is a botanical inhaled investigational...

November 29, 2021

Category - Developments

ENDRA, King ’s College Hospital in TAEUS clinical study for NAFLD

Palisade Bio to receive U.S. patent to treat adhesions and postoperative ileus

Cognetivity, Ketamine One collaborating on depression, PTSD studies

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Altamira randomizes first patient in Bentrio trial in seasonal allergic rhinitis

Clene presents updated data from RESCUE-ALS Phase 2 study

BeyondSpring receives CRL for plinabulin NDA to prevent CIN

Palisade Bio to receive European patent for LB1148

Hepion receives FDA fast track designation for CRV431 to treat NASH

Tetra Bio-Pharma posts positive initial data from ongoing Phase 2 trials of QIXLEEF

General

More